Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Jenna who wrote (30695)	4/1/1999 3:59:00 PM
From: Adelle	Read Replies (1) \| Respond to of 120523

Jenna, from now on, if the word comes out of your mouth, I will buy it.

To: Jenna who wrote (30695)	4/1/1999 4:03:00 PM
From: violatrader	Respond to of 120523

What a dope I was to sell ewbx so quickly. Oh well, learning. I got a profit but I could have really had a big profit. Could of, should of??? Emily

To: Jenna who wrote (30695)	4/1/1999 11:03:00 PM
From: robert baldwin	Read Replies (3) \| Respond to of 120523

Jenna, I'm new to the Market Gems thread and have been very impressed with the insight you have provided to people. My question is a fundamental one: what do you do when you've closed a position on a stock at 10% loss and then it surges 25%? I sold my position in DRIV in mid-March when its TA still looked questionable (MACD lines converged below the center line, consistently down day volume, etc.) and there was very little news about new alliances. I assumed (incorrectly!) that an uptrend would be several months away, but knew that it would most certainly be driven by some sort of major deal with an e-tailer (Amazon, most likely). Clearly, big share blocks are being bought in anticipation of something-further, technicals look very good (MACD fast line just crossed the center line, third highest daily volume, etc.). I suppose profit is profit, even if you make it off of a smaller base of capital from selling previously at a loss. If DRIV really is starting to trend up hard, $45 to $50 may be a good entry point for a significant push upward. I'd very much appreciate your opinion. Regards, Robert

To: Jenna who wrote (30695)	4/3/1999 12:00:00 PM
From: violatrader	Respond to of 120523

Jenna - I was thinking of what to recommend for a friend who owns dow dogs and is unhappy (DUH?) so I thought of qqq for him. He just wants to buy something that he can put away and forget about for long-term and make money. So I pulled up the chart and look: it is a beautiful cup and handle. Yes? Thinking of buying some for myself too for my "longterm" (Yeah, right, what's long-term for you Emily, 2 weeks?) account. Whatcha think? Emily

To: Jenna who wrote (30695)	4/6/1999 10:51:00 AM
From: violatrader	Respond to of 120523

Jenna Are you still holding DRTE? Do you think it's gonna turn soon????? Thanks, Emily

To: Jenna who wrote (30695)	4/6/1999 11:21:00 AM
From: violatrader	Read Replies (1) \| Respond to of 120523

Maybe this will help? Home - Yahoo! - Help -------------------------------------------------------------------------------- Click here for Multex [ Business \| US Market \| By Industry \| IPO \| AP \| S&P \| International \| PRNews \| BizWire ] -------------------------------------------------------------------------------- Related Quotes DRTE 20 1/8 -1 delayed 20 mins - disclaimer Tuesday April 6, 10:10 am Eastern Time Company Press Release Major Midwestern US Pharmaceutical Company Selects Dendrite to Create New Levels of Sales Force Effectiveness MORRISTOWN, N.J.--(BUSINESS WIRE)--April 6, 1999--Dendrite International, Inc. (NASDAQ/NMS:DRTE - news), today announced it has been selected by a major pharmaceutical company to implement both ForcePharma and a palmtop solution. In addition, Dendrite will provide ongoing customer support services for its U.S. sales force of 1,700 professionals, including sales representatives, managers and managed care specialists. John Bailye, President and CEO, said, ''We are delighted that we were chosen as the long-term sales and marketing partner for one of the leaders in the pharmaceutical industry. We are committed to be a valuable part of their ongoing success.'' After an exhaustive study and review process, Dendrite was selected over both traditional and specialized newer vendors in this market space. Although the company was positively influenced by the technology of ForcePharma over the competitive offerings, it was Dendrite's reputation for on-time implementation and very high quality supporting user services that formed the basis of the final choice. Bailye added, ''Dendrite's highly specialized product and service offerings best support the client's goals as a market leader in the pharmaceutical industry. We were evaluated against all competitors, and our customers came to realize that it's Dendrite's products and services, when coupled with our company's knowledge and pharmaceutical experience, that delivers superior overall results to the client's sales teams.'' ABOUT DENDRITE With a strong focus on outcomes in the Pharmaceutical and Consumer Package Goods (CPG) industries, Dendrite is a leading global provider of highly-specialized, integrated product and service offerings to support strategies for a sustained competitive advantage. Thousands of sales representatives and their managers in over 150 major corporations in 17 countries rely on Dendrite for a uniquely tailored combination of tools, information and skills to help them prepare for tomorrow's challenges and improve their sales success. The Company uses its highly specialized industry knowledge to develop modular software products that enhance sales force effectiveness (SFE). The products, combined with specifically tailored coaching and support services, focus sales representatives on improving their performance. With a global infrastructure as its foundation, Dendrite's commitment to unparalleled service has been the hallmark of the business and the basis of strong customer loyalty since the Company's inception. ForcePharma is the newest sales force effectiveness (SFE) software product from Dendrite specifically developed for the pharmaceutical industry. This highly configurable tool set meets the requirements of each user type, saving the expense and time of extensive customization to support sales reps and their managers. ForcePharma ensures sales force effectiveness and productivity by providing easy access to actionable information in a concise and clear format. The new generation product provides insight into influence within the pharmaceutical marketplace - one of the most vital variables in sales growth and information distribution. Headquartered in Morristown, New Jersey, Dendrite employs over 800 people all around the world. For more information, visit the Company's Web site: drte.com. Note: Dendrite is a registered trademark of Dendrite International, Inc. This press release may contain statements that, if not verifiable historical fact, may be viewed as forward-looking statements that could predict future events or outcomes with respect to Dendrite and its business. The predictions embodied in these statements will involve risks and uncertainties and, accordingly, Dendrite's actual results may differ significantly from the results discussed or implied in such forward-looking statements. -------------------------------------------------------------------------------- Contact: John Bailye, CEO George Robson, CFO Erik Hawkinson, Investor Relations 973/425-1200 -------------------------------------------------------------------------------- More Quotes and News: Dendrite International Inc (Nasdaq:DRTE - news) Related News Categories: computers, medical/pharmaceutical, software -------------------------------------------------------------------------------- Help -------------------------------------------------------------------------------- Copyright © 1999 Business Wire. All rights reserved. All the news releases provided by Business Wire are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving ina public database, redistributing via a computer network or in a printed form. See our Important Disclaimers and Legal Information. Questions or Comments?